NYSE$AVTR
Avantor Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported solid financial results with bioprocessing outperformance and laboratory solutions segment growth.
Avantor reported a slight decrease in net sales but demonstrated strength in bioprocessing and laboratory solutions. The company is raising its free cash flow guidance for the year, driven by a disciplined approach to working capital and cost transformation programs running ahead of plan.
- Net sales were $1.71 billion, a decrease of 0.3% year-over-year with an organic decline of 0.7%.
- Net income was $57.8 million, with an adjusted EBITDA of $302.5 million.
- Diluted GAAP EPS was $0.08, while adjusted EPS was $0.26.
- Operating cash flow was $244.8 million, and free cash flow was $204.0 million.
Headline financials
Revenue & EPS history
Avantor · Revenue · Quarterly
$1.71B
Forward guidance
Avantor is on track to realize mid to high single-digit growth in its bioprocessing business and is well-positioned to achieve its full-year guidance.
Tailwinds
- Continued momentum in order intake in the bioprocessing business.
- Cost transformation programs are running ahead of plan.
- Expected mid to high single-digit growth in the bioprocessing business.
- Focus on delivering long-term growth for Avantor.
- Commitment to providing differentiated value to customers and shareholders.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.6%
Avg return
Earnings day
-0.9%
Avg return
5 days after
+1.3%
Avg return
30 days after
47%
15 / 32 earnings
Positive
+21.7%
Q1 2020
Best reaction
-23.2%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | +1.5% | +16.0% | |
| Q4 2025 | -13.6% | -17.6% | -28.9% | |
| Q3 2025 | -23.2% | -22.5% | -22.2% | |
| Q1 2025 | -16.6% | -16.2% | -18.1% | |
| Q4 2024 | -11.7% | -16.8% | -19.4% | |
| Q3 2024 | -2.7% | -3.5% | -10.7% | |
| Q2 2024 | +15.0% | +17.2% | +12.4% | |
| Q1 2024 | -4.3% | -2.9% | -4.0% | |
| Q4 2023 | +8.6% | +7.3% | +13.3% | |
| Q3 2023 | -12.1% | -10.8% | +4.1% | |
| Q2 2023 | -9.9% | -7.9% | -4.6% | |
| Q1 2023 | +8.0% | +7.8% | +10.2% | |
| Q4 2022 | -5.9% | -1.9% | +0.9% | |
| Q3 2022 | -1.8% | -6.1% | +4.4% | |
| Q2 2022 | -8.6% | -7.9% | -19.6% | |
| Q1 2022 | +8.4% | +7.4% | +12.1% | |
| Q4 2021 | -2.9% | -3.6% | -13.5% | |
| Q3 2021 | +9.3% | +7.9% | +7.3% | |
| Q2 2021 | +0.3% | +0.9% | +4.8% | |
| Q1 2021 | -1.4% | -5.7% | -3.0% | |
| Q4 2020 | -2.2% | -1.9% | -9.9% | |
| Q3 2020 | -5.5% | -5.9% | +5.3% | |
| Q2 2020 | +16.6% | +18.3% | +16.0% | |
| Q1 2020 | +21.7% | +22.8% | +37.4% | |
| Q4 2019 | -11.4% | -7.5% | -21.5% | |
| Q3 2018 | +2.7% | -4.2% | +17.4% | |
| Q3 2019 | +2.7% | -4.2% | +17.4% | |
| Q2 2019 | +4.2% | +5.2% | +7.3% | |
| Q1 2018 | +4.2% | +5.2% | +7.3% | |
| Q2 2018 | +4.2% | +5.2% | +7.3% | |
| Q1 2019 | +4.2% | +5.2% | +7.3% | |
| Q4 2018 | +4.2% | +5.2% | +7.3% | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro